Dr. Rogers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
5th Floor
Columbus, OH 43210Phone+1 614-366-9338Fax+1 614-293-4812
Education & Training
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
- University of MichiganResidency, Internal Medicine, 2008 - 2011
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2008
Certifications & Licensure
- OH State Medical License 2012 - 2026
- MI State Medical License 2008 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance Start of enrollment: 2020 Mar 11
- Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2021 Mar 18
- Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2015 Aug 03
- Join now to see all
Publications & Presentations
PubMed
- 34 citationsVentricular arrhythmias and sudden death events following acalabrutinib initiation.Seema A Bhat, John Gambril, Leylah Azali, Sunnia T Chen, Lindsay Rosen
Blood. 2022-11-17 - 7 citationsPatient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.Adam S Kittai, Ying Huang, Kyle A Beckwith, Seema A Bhat, David A Bond
American Journal of Hematology. 2023-01-01 - 110 citationsCumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.Tracy Wiczer, Lauren B. Levine, Jessica Brumbaugh, Jessica Coggins, Qiuhong Zhao
Blood Advances. 2017-09-12
Abstracts/Posters
- Restoring Functional Deficits in Older Adults with Hematologic MalignancyKerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in LeukemiaKerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected CytotoxicityKerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicent...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
- Debate: Should Patients with CLL Take Breaks from Targeted Therapies?September 11th, 2024
- ‘Promising’ New Txs for Most Common Adult LeukemiaSeptember 8th, 2023
- Ibrutinib Effective Treatment for Difficult to Treat Forms of Hairy Cell LeukemiaJuly 23rd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: